IN2015KN00015A - - Google Patents
Info
- Publication number
- IN2015KN00015A IN2015KN00015A IN15KON2015A IN2015KN00015A IN 2015KN00015 A IN2015KN00015 A IN 2015KN00015A IN 15KON2015 A IN15KON2015 A IN 15KON2015A IN 2015KN00015 A IN2015KN00015 A IN 2015KN00015A
- Authority
- IN
- India
- Prior art keywords
- masp
- inhibitory agent
- disease
- subject
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
In one aspect, the invention provides methods and compositions for inhibiting MASP-3 -dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3 -dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661167P | 2012-06-18 | 2012-06-18 | |
| PCT/US2013/046432 WO2013192240A2 (en) | 2012-06-18 | 2013-06-18 | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015KN00015A true IN2015KN00015A (en) | 2015-07-31 |
Family
ID=49769678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN15KON2015 IN2015KN00015A (en) | 2012-06-18 | 2013-06-18 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20130344073A1 (en) |
| EP (4) | EP3058951A1 (en) |
| JP (4) | JP6445972B2 (en) |
| KR (4) | KR102339315B1 (en) |
| CN (3) | CN109908352A (en) |
| AU (3) | AU2013277309B2 (en) |
| BR (1) | BR112014031522A2 (en) |
| CA (2) | CA2875567C (en) |
| CL (2) | CL2014003455A1 (en) |
| CY (1) | CY1124234T1 (en) |
| DK (1) | DK2861246T3 (en) |
| ES (1) | ES2864857T3 (en) |
| HK (1) | HK1209623A1 (en) |
| HR (1) | HRP20210559T1 (en) |
| HU (1) | HUE053727T2 (en) |
| IL (2) | IL236327B (en) |
| IN (1) | IN2015KN00015A (en) |
| LT (1) | LT2861246T (en) |
| MX (3) | MX2014015715A (en) |
| NZ (1) | NZ629473A (en) |
| PL (1) | PL2861246T3 (en) |
| PT (1) | PT2861246T (en) |
| RS (1) | RS61755B1 (en) |
| RU (2) | RU2019140356A (en) |
| SI (1) | SI2861246T1 (en) |
| WO (1) | WO2013192240A2 (en) |
| ZA (1) | ZA201500094B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937046B2 (en) | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| PL3287142T3 (en) | 2011-04-08 | 2021-12-27 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
| US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| NZ729747A (en) | 2013-03-15 | 2020-03-27 | Omeros Corp | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| KR20210130260A (en) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Fc region variant |
| EP2983710B1 (en) * | 2013-04-09 | 2019-07-31 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| ES2753419T3 (en) * | 2013-06-07 | 2020-04-08 | Univ Duke | Complement factor H inhibitors |
| NZ715455A (en) | 2013-07-09 | 2021-12-24 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| EP3057993B1 (en) | 2013-10-17 | 2020-08-12 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| EP3151845A4 (en) * | 2014-06-05 | 2018-01-17 | The Regents of the University of Colorado, a body corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| BR112017009297B1 (en) | 2014-11-05 | 2024-02-15 | Annexon, Inc | HUMANIZED C1Q COMPLEMENT ANTIFATOR ANTIBODIES, PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME, THERAPEUTIC USE THEREOF, ISOLATED POLYNUCLEOTIDE, ISOLATED HOST CELL, AS WELL AS IN VITRO METHODS FOR DETECTING SYNAPSES |
| US10639307B2 (en) | 2015-05-15 | 2020-05-05 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides |
| CA2987976A1 (en) * | 2015-06-03 | 2016-12-08 | Coyne Ip Holdings, Llc | Methods for establishing threshold limits for a chemical or biological agent in a target species |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (en) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| KR102432062B1 (en) * | 2015-11-09 | 2022-08-12 | 오메로스 코포레이션 | Methods for treating conditions associated with masp-2 dependent complement activation |
| CN115260310A (en) | 2015-11-24 | 2022-11-01 | 安尼艾克松股份有限公司 | FAB fragment of anti-complement factor C1Q and application thereof |
| US10736960B2 (en) * | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| IL305200A (en) | 2016-03-31 | 2023-10-01 | Omeros Corp | Masp-2 inhibitory agents for use in inhibiting angiogenesis |
| JOP20170154B1 (en) | 2016-08-01 | 2023-03-28 | Omeros Corp | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
| JOP20170170B1 (en) | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018186322A1 (en) * | 2017-04-03 | 2018-10-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-masp-1 antibodies and methods of use |
| AU2018322032A1 (en) * | 2017-08-25 | 2020-03-12 | Omeros Corporation | Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome |
| BR112020018357A2 (en) * | 2018-04-13 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | ANTICOMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE |
| EP3836965A4 (en) * | 2018-06-22 | 2022-04-20 | Omeros Corporation | Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders |
| KR20210057086A (en) | 2018-09-06 | 2021-05-20 | 아칠리온 파르마세우티칼스 인코포레이티드 | The morphological form of Danicopan |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| BR112021005506A2 (en) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | morphic forms of complementary factor inhibitors d |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| EP3966226A1 (en) | 2019-05-07 | 2022-03-16 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| US20210171461A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| JP2023504543A (en) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | MASP-2 inhibitors and methods of use |
| IL293588A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
| CN115052862A (en) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | MASP-2 inhibitors and methods of use |
| CN112237630A (en) * | 2020-02-21 | 2021-01-19 | 中国人民解放军军事科学院军事医学研究院 | Application of substance aiming at MASP-2, coronavirus N protein or combination thereof in preparation of drugs for diseases caused by coronaviruses |
| TW202319069A (en) * | 2020-03-06 | 2023-05-16 | 美商奥默羅斯公司 | Methods of inhibiting masp-2 for the treatment and/or prevention of acute respiratory distress syndrome, pneumonia or some other pulmonary manifestation of influenza virus infection induced by influenza virus |
| CN115215937B (en) | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | Anti-human MASP-2 antibody, preparation method and application thereof |
| CN114989259B (en) * | 2022-05-27 | 2023-06-09 | 成都佩德生物医药有限公司 | Small molecule peptide Ped4 and application thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
| JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| CA2391402A1 (en) * | 1999-12-02 | 2001-06-07 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| PT1344533E (en) * | 2002-03-15 | 2007-01-31 | Natimmune As | Pharmaceutical compositions comprising mannose binding lectin |
| ES2601143T3 (en) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom. |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| AU2004216176B2 (en) * | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| WO2005005630A2 (en) * | 2003-07-08 | 2005-01-20 | Umc Utrecht Holding B.V. | Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| EP3530288A3 (en) * | 2004-06-10 | 2019-12-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CN100518905C (en) * | 2004-11-02 | 2009-07-29 | 浙江欧美环境工程有限公司 | Turning type electric desalinization device |
| WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2626356C (en) * | 2005-10-21 | 2017-08-22 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| RU2477137C2 (en) * | 2006-03-08 | 2013-03-10 | АРКЕМИКС Эл Эл Си | Complement-binding aptamers and c5 agents applicable for treating ocular disorders |
| CA2685714C (en) | 2007-05-31 | 2016-04-12 | University Of Washington | Inducible mutagenesis of target genes |
| CA2742802C (en) * | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| US20110002931A1 (en) * | 2009-06-23 | 2011-01-06 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| AU2010272483B2 (en) * | 2009-07-17 | 2016-07-21 | Omeros Corporation | MASP isoforms as inhibitors of complement activation |
| PT2488203T (en) * | 2009-10-16 | 2017-03-10 | Univ Leicester | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| CA2791841C (en) * | 2010-03-05 | 2023-01-03 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| US8795973B2 (en) * | 2010-11-29 | 2014-08-05 | University of Leceister | Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof |
| PL3287142T3 (en) * | 2011-04-08 | 2021-12-27 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| SI2833907T1 (en) * | 2012-04-06 | 2018-07-31 | Omeros Corporation | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
-
2013
- 2013-06-18 BR BR112014031522A patent/BR112014031522A2/en not_active Application Discontinuation
- 2013-06-18 CN CN201811331359.1A patent/CN109908352A/en active Pending
- 2013-06-18 RU RU2019140356A patent/RU2019140356A/en unknown
- 2013-06-18 KR KR1020207027432A patent/KR102339315B1/en active IP Right Grant
- 2013-06-18 CA CA2875567A patent/CA2875567C/en active Active
- 2013-06-18 IN IN15KON2015 patent/IN2015KN00015A/en unknown
- 2013-06-18 CN CN202210652007.6A patent/CN115040653A/en active Pending
- 2013-06-18 EP EP16150858.5A patent/EP3058951A1/en active Pending
- 2013-06-18 EP EP13807326.7A patent/EP2861246B1/en active Active
- 2013-06-18 PT PT138073267T patent/PT2861246T/en unknown
- 2013-06-18 CA CA3214532A patent/CA3214532A1/en active Pending
- 2013-06-18 US US13/921,139 patent/US20130344073A1/en not_active Abandoned
- 2013-06-18 KR KR1020227022627A patent/KR20220100997A/en not_active Application Discontinuation
- 2013-06-18 EP EP21152111.7A patent/EP3878865A3/en not_active Withdrawn
- 2013-06-18 KR KR1020207003537A patent/KR20200015952A/en not_active Application Discontinuation
- 2013-06-18 JP JP2015518524A patent/JP6445972B2/en active Active
- 2013-06-18 ES ES13807326T patent/ES2864857T3/en active Active
- 2013-06-18 PL PL13807326T patent/PL2861246T3/en unknown
- 2013-06-18 DK DK13807326.7T patent/DK2861246T3/en active
- 2013-06-18 KR KR20157001304A patent/KR20150031298A/en not_active IP Right Cessation
- 2013-06-18 AU AU2013277309A patent/AU2013277309B2/en active Active
- 2013-06-18 MX MX2014015715A patent/MX2014015715A/en unknown
- 2013-06-18 LT LTEP13807326.7T patent/LT2861246T/en unknown
- 2013-06-18 RS RS20210465A patent/RS61755B1/en unknown
- 2013-06-18 EP EP22177615.6A patent/EP4119577A3/en active Pending
- 2013-06-18 SI SI201331873T patent/SI2861246T1/en unknown
- 2013-06-18 HU HUE13807326A patent/HUE053727T2/en unknown
- 2013-06-18 RU RU2015101230A patent/RU2709351C2/en active
- 2013-06-18 NZ NZ629473A patent/NZ629473A/en unknown
- 2013-06-18 CN CN201380044434.5A patent/CN104717975A/en active Pending
- 2013-06-18 WO PCT/US2013/046432 patent/WO2013192240A2/en active Application Filing
-
2014
- 2014-12-17 MX MX2020005700A patent/MX2020005700A/en unknown
- 2014-12-17 IL IL236327A patent/IL236327B/en active IP Right Grant
- 2014-12-17 MX MX2019012909A patent/MX2019012909A/en unknown
- 2014-12-18 CL CL2014003455A patent/CL2014003455A1/en unknown
-
2015
- 2015-01-07 ZA ZA2015/00094A patent/ZA201500094B/en unknown
- 2015-10-22 HK HK15110361.3A patent/HK1209623A1/en unknown
-
2016
- 2016-12-22 CL CL2016003297A patent/CL2016003297A1/en unknown
-
2018
- 2018-06-15 AU AU2018204285A patent/AU2018204285B2/en active Active
- 2018-08-28 IL IL261436A patent/IL261436B/en unknown
- 2018-09-14 US US16/131,871 patent/US20190127484A1/en not_active Abandoned
- 2018-11-30 JP JP2018224961A patent/JP6771531B2/en active Active
-
2020
- 2020-05-06 AU AU2020202999A patent/AU2020202999B2/en active Active
- 2020-09-29 JP JP2020163180A patent/JP2021006546A/en active Pending
-
2021
- 2021-04-08 HR HRP20210559TT patent/HRP20210559T1/en unknown
- 2021-04-20 CY CY20211100342T patent/CY1124234T1/en unknown
- 2021-10-11 US US17/498,559 patent/US20220259325A1/en not_active Abandoned
-
2022
- 2022-04-01 JP JP2022062008A patent/JP2022084946A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015KN00015A (en) | ||
| MX2019004616A (en) | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors. | |
| MX2019015580A (en) | Methods for treating huntington's disease. | |
| MX2015004565A (en) | Laquinimod for reducing thalamic damage in multiple sclerosis. | |
| MX2017002144A (en) | Modified double-stranded rna agents. | |
| CY1119420T1 (en) | NEW THERAPEUTIC APPROACHES TO PARKINSON'S DISEASE TREATMENT | |
| MX2016014634A (en) | Compounds for treating ophthalmic diseases and disorders. | |
| MX2017016424A (en) | Compounds for use in treating neuromuscular disorders. | |
| IN2014CN03465A (en) | ||
| MX343687B (en) | Tricyclic sulfonamide compounds and methods of making and using same. | |
| NZ629675A (en) | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria | |
| EA201491199A1 (en) | NANOPARTICLES INCLUDING METAL MATERIAL AND MATERIAL HAFNIUM OXIDE, COMPOSITION AND ITS APPLICATION | |
| EA201300471A1 (en) | SUBSTITUTED 6-AMINONICOTINAMIDES AS KCNQ2 / 3 MODULATORS | |
| EA201590654A1 (en) | COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON'S DISEASE | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2018003569A (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses. | |
| MX2013011691A (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses. | |
| MX2015012741A (en) | Deuterated palbociclib. | |
| CY1116234T1 (en) | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2 / 3 conformers | |
| WO2012139069A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
| MX343589B (en) | Leukotoxin e/d as a new anti-inflammatory agent and microbicide. | |
| CY1116158T1 (en) | Substituted 2-oxo- and 2-thiooxy-dihydroquinoline-3-carboxamides as KCNQ2 / 3 modulators | |
| MX2015006779A (en) | Protein slurp-1 for use in the treatment of ocular diseases. | |
| MX2014011843A (en) | Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma. | |
| MX368084B (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions. |